A Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3-OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)
Diabetologie und Stoffwechsel · 01.04.2023 · 18 (S 01 S 01) · S54
DOI: 10.1055/s-0043-1767968 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologie und Stoffwechsel, erschienen am 01.04.2023. Verfasst von Michael G. Ison und 14 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
RSV-associated acute respiratory infections (ARI), particularly lower respiratory tract diseases (LRTD), present a significant disease burden in older adults. Results from an ongoing study show the vaccine efficacy (VE) of the AS01E-adjuvanted RSVPreF3-OA in adults ≥60 YOA.
Methods
This phase 3, observer-blind, placebo-controlled, (NCT04886596) enrolled adults ≥60 YOA in several countries. Participants were randomized (1:1) to receive a single dose of RSVPreF3-OA or placebo before the RSV season. The primary objective was to demonstrate VE of a single dose of RSVPreF3-OA in preventing RSV-confirmed (qRT-PCR) LRTD during one RSV season. VE is reported also against severe RSV-confirmed LRTD, RSV-confirmed ARI, RSV-confirmed LRTD and RSV-confirmed ARI.
Results
A total of 26,664 participants were enrolled, of whom 24,960 (RSVPreF3-OA: 12,466; placebo: 12,494) were included in the efficacy analysis. The mean age was 69.5 (±6.5) years. Over a median follow-up of 6.7 months, 47 RSV-confirmed LRTD episodes were reported (RSVPreF3-OA: 7; placebo: 40), resulting in a VE of 82.6% (96.95% CI: 57.9–94.1), thus the primary objective was met. Consistently high VE across the clinical spectrum of RSV disease, from RSV-confirmed ARI (71.7% [95% CI: 56.2–82.3]) to severe RSV-confirmed LRTD (94.1% [95% CI: 62.4–99.9]) was observed. High VE was seen in different age groups and regardless of RSV subtype, baseline comorbidity or pre-frail status.
Conclusion
A single RSVPreF3-OA dose is highly efficacious against RSV-confirmed LRTD and RSV-confirmed ARI in adults ≥60 YOA, regardless of RSV disease severity, RSV subtype, baseline comorbidity and pre-frail status. Publication History Article published online: 02 May 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Ison, M. G., Papi, A., Langley, J. M., Lee, D., Leroux-Roels, I., Martinon-Torres, F., Schwarz, T. F., Zyl-Smit, R. N. V., Dezutter, N., Schrevel, N. D., Fissette, L., David, M., Wielen, M. V. D., Kostanyan, L., & Hulstrøm, V. (2023). A Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3-OA) is Efficacious in Adults ≥ 60 Years of Age (YOA). Diabetologie und Stoffwechsel, 18(S 01 S 01), S54. https://doi.org/10.1055/s-0043-1767968
Vancouver
Ison MG, Papi A, Langley JM, Lee D, Leroux-Roels I, Martinon-Torres F, et al. A Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3-OA) is Efficacious in Adults ≥ 60 Years of Age (YOA). Diabetologie und Stoffwechsel. 2023;18(S 01 S 01):S54. doi:10.1055/s-0043-1767968
BibTeX
@article{Ison2023,
author = {Ison, Michael G. and Papi, Alberto and Langley, Joanne M. and Lee, Dong-Dun and Leroux-Roels, Isabel and Martinon-Torres, Federico and Schwarz, Tino F. and Zyl-Smit, Richard N. van and Dezutter, Nancy and Schrevel, Nathalie De and Fissette, Laurence and David, Marie-Pierre and Wielen, Marie Van Der and Kostanyan, Lusine and Hulstrøm, Veronica},
title = {A Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3-OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)},
journal = {Diabetologie und Stoffwechsel},
year = {2023},
volume = {18},
number = {S 01 S 01},
pages = {S54},
doi = {10.1055/s-0043-1767968}
}
EUVIMED